Press Releases

CPhI Festival of Pharma (5-16 October, 2020), the world’s largest ever virtual pharma expo, unveils its ground-breaking two-week long agenda. The newly launched and rapidly created virtual event will provide the global pharma community with a vital platform to meet and exchange ideas – at a time when the industry is still adapting to remote ways of working. The CPhI Festival of Pharma will see global industry heavyweights join forces with more than 20,000 attendees, in w

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company has entered into a Clinical Trial Agreement (CTA), dated August 28, 2020, with the Board of Regents of the University of Wisconsin System (UWS) to conduct a clinical study entitled, “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” Unde

Sorrento Therapeutics, Inc. and SmartPharm Therapeutics, Inc. (“SmartPharm”) announced that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.  The platform in synergy with Sorrento’s industry-leading fully human G-MAB™ antibody library has t

Oxford Biomedica plc, a leading gene and cell therapy group, announced today that it has signed an 18 month supply agreement under a three year Master Supply and Development Agreement (“the Agreement”) with AstraZeneca UK Ltd (“AstraZeneca”) for large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222. The Parties may extend the supply period for AZD1222 by a further 18 months into 2022 and 2023 by mutual agreement.

Boston Pharmaceuticals announced an agreement with Novartis through which Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH). NASH occurs in 12 percent of patients with nonalcoholic fatty liver disease (NAFLD) when the liver becomes inflamed and fibrotic. A deficiency in fibroblast growth factor 21 (FGF21) favors the development of steatosis, inflammation, hepatocyte

Luina Bio, one of Australia’s most experienced biopharmaceutical contract development and manufacturing (CDMO) organisations, is pleased to announce several expansion plans to meet the increasing demand in the microbiome and recombinant biopharma markets. The first stage of the expansion will see Luina open additional small scale (30L) GMP manufacturing suite in late 2020, broadening he company’s service offering for new clinical projects that need small scale GMP facili

Enigma Biomedical Group (EBG) announced execution of a Master Development, License and Option Agreement and two Project Agreements to evaluate novel neuroimaging biomarkers from Janssen Pharmaceutica N.V. (Janssen), part of The Janssen Pharmaceutical Companies of Johnson & Johnson. These agreements permit EBG to evaluate Janssen’s PET ligands, and if such evaluation is favorable, grant to EBG an option to negotiate an exclusive license to each PET ligand. The first two (2) PET ligan

Elektrofi, Inc., a Boston-based biotechnology company focused on drug formulation and delivery innovations, and LEO Pharma A/S, a global leader in medical dermatology, today announced an exclusive license agreement to develop subcutaneously administered antibodies using Elektrofi’s high-concentration, low-volume delivery technology. Under the terms of the agreement, Elektrofi will license its proprietary technology to LEO Pharma for LEO Pharma’s use and will codevelop im

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved the Investigational New Drug (IND) application from the company for the Phase I clinical trial with CT-P59, which is an antiviral treatment candidate with antibodies to COVID-19. Celltrion has begun the enrollment of patients with mild symptoms of SARS-CoV-2 infection and the clinical trial has been developed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT -P5

HJB, a biologics Contract Development and Manufacturing Organization (CDMO) committed to quality, reliability and speed for each and every CMC package delivered to its partners, announces it enters into a strategic partnership for CMC development and manufacturing with Ansun Biopharma ("Ansun"), a clinical stage biopharmaceutical company, on its therapeutic biologics pipeline. The first program is expecting to submit an Investigational New Drug (IND) application in 2021. U